IR-MED INC - IRME STOCK NEWS

IR-MED Inc. (OTCQB:IRME) has appointed Ran Ziskind as its new Chief Executive Officer, effective September 1, 2024. Ziskind, a tech entrepreneur and growth manager, brings two decades of experience in launching and expanding innovative companies. He was previously co-founder and CEO of Galatea , where he developed groundbreaking electro-optics technology for the diamond industry. Ziskind's expertise spans research and development, intellectual property management, and product commercialization.

IR-MED, developer of a noninvasive AI-driven spectrographic analysis technology platform for healthcare, is preparing to launch its first product, PressureSafe™. The company aims to improve healthcare outcomes through early, non-invasive detection of skin, tissue, and blood vessel-related conditions. With Ziskind's leadership, IR-MED plans to capture market share and set new standards in detection and diagnosis.

IR-MED Inc. (OTCQB:IRME) has been awarded 'Best Up-and-Coming Health Tech Company' at the prestigious Netty Awards, recognizing its innovative AI-driven spectrographic analysis technology platform. The company's 'Sensing the Invisible' technology aims to enhance healthcare through early detection of various medical conditions.

IR-MED's flagship products include PressureSafe™, set to launch in the U.S. in late 2024, which identifies early-stage pressure injuries with 92% accuracy, addressing a $26.8 billion market. DiaSafe™, planned for launch in 2025, targets the diabetic foot ulcer detection market, projected to reach $17.1 billion by 2031.

The company's technology provides non-invasive, skin tone agnostic, real-time analysis of blood and tissue, potentially revolutionizing patient care and treatment paradigms in multi-billion dollar markets.

IR-MED Inc. (OTCQB:IRME) has received a $500,000 grant from the Israel Innovation Authority to develop DiaSafe™, a device for early detection of diabetic foot ulcers. This marks the company's second IIA grant after peer review. DiaSafe™ uses AI-driven spectrographic analysis to provide non-invasive, real-time optical readings of biomarkers. The 13-month development is on schedule, with computer simulations completed and hardware construction underway.

Diabetic foot ulcers affect up to 183 million people globally, with 37 million potentially requiring amputation. Early detection can significantly improve patient outcomes and reduce healthcare costs in a $10 billion global treatment market. IR-MED's platform technology also powers PressureSafe™, a device for early pressure injury detection, expected to launch in the U.S. in H2 2024.

IR-MED has published positive results from a usability study of its PressureSafe™ device, performed in collaboration with Clalit, Israel's largest HMO. The study, which included 924 scans on 154 body locations, demonstrated that PressureSafe™ could reduce pressure injuries by 50%. The device achieved 92% sensitivity and 88% specificity in detecting Stage 1 and suspected deep tissue injury pressure injuries. PressureSafe™, which uses AI-driven infra-red spectroscopy, has received FDA listing confirmation. The findings were also presented at the National Pressure Injury Advisory Panel (NPIAP) 2024 Annual Conference.

IR-MED Inc. achieves a significant milestone with the FDA listing of PressureSafe™ device for early detection of pressure injuries in the U.S. market. The device uses AI-driven spectrographic analysis technology to address healthcare needs, potentially revolutionizing patient care and safety.

IR-MED Inc. reports highly favorable proof of efficacy data for PressureSafe™, a decision support device utilizing AI and infra-red spectroscopy to detect pressure injuries early. The study conducted at Clalit medical centers showed 92% sensitivity and 88% specificity in detecting early-stage pressure injuries, reducing pressure injuries incidence by 50%. The device is deemed safe, efficient, and valuable for early detection, especially in patients with darker skin tones.

IR-MED Inc. announces final data from a study conducted at Clalit medical centers on PressureSafe, an AI-driven technology for pressure injury detection. The study results will be presented at the NPIAP 2024 Annual Conference, showcasing PressureSafe's efficacy in early-stage pressure injury detection.

IR-MED Inc. (OTCQB:IRME) has been awarded the 'Most Innovative Non-Invasive Diagnostics Technology Developer 2023 – Israel' by UK-based Corporate Vision Magazine for its PressureSafe™ device and technology platform. The non-invasive device is more than 90% accurate in detecting pressure injuries and is expected to launch in the U.S. in the first half of 2024, subject to regulatory approval. Pressure injuries cost the U.S. healthcare system $26.8 billion and lead to 60,000 deaths annually.

IR-MED Inc. (OTCQB:IRME) has been granted a patent for its PressureSafe™ decision support device, which offers more than 90% accuracy in the early detection of pressure injuries. The company's noninvasive AI-driven spectrographic analysis technology platform aims to address significant healthcare needs, with the U.S. healthcare burden from pressure injuries amounting to $26.8 billion annually. The patent, titled 'System and method for noninvasive analysis of tissue,' covers IR-MED's platform technology, a method for noninvasive analysis of subcutaneous tissue. This method uses infrared radiation (IR) to measure the intensity of the radiation in spectral bands emerging from the tissue, providing data-driven support for the diagnostic assessment of subcutaneous tissue. IR-MED's first product, PressureSafe™, is set to launch in the U.S. in the first half of 2024, offering a novel solution to the challenge of treating pressure injuries, particularly for people with darker skin tones.